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2002 and £335 million in UK during 2001. CONCLUSIONS: Ulipristal appears as 
effective as levonorgestrel in preventing unintended pregnancies with similar safety 
proﬁ le. Substantial cost-savings can be expected with appropriate awareness programs 
about emergency contraceptives among women.
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OBJECTIVES: To examine the characteristics of patients admitted to PICU with RSV 
infection following provincial approval of RSV prophylaxis in June 2002. Secondly, to 
determine if patients had received palivizumab and document incurred morbidities. 
METHODS: A retrospective, hospital medical records review of all PICU admissions 
for RSV infection from January 1, 2003 to December 31, 2009. RSV infection was 
identiﬁ ed by ICD codes and cases were conﬁ rmed by RSV IFA test, culture, or PCR. 
Data was collected on baseline demographics, underlying disease, criteria for hospi-
talization, type of respiratory illness and management, complications and palivizumab 
prophylaxis. Group 1 patients (≤2 years) were compared to Group 2 (>2–18 years). 
RESULTS: A total of 181 patients were admitted with RSV infection over 7 years. 
Group 1 (n = 152); Group 2 (n = 29) had a mean admission age in months (SD); 3.7 
(5.7) versus 59.9 (37.7). Majority (79.6%) Group 1 versus only 20.7% Group 2 (P 
< 0.001) had no underlying disease. 97.4% versus 93.1% were admitted with respira-
tory distress and most had bronchiolitis; 88.8% versus 55.2 % (P < 0.001), decreased 
oxygen saturation; 77% versus 75.9% and inability to maintain intake; 75.7% versus 
44.8% (P < 0.01). Fifty percent versus 41.3% required mechanical ventilation and 
81.6% versus 69.0% received antibiotics. Median days (range) in PICU was 5 (1–73) 
versus 2 (1–36). Median length of hospital stay days (range) was 9 (1–113) versus 7 
(1–64) (P < 0.05). The overall RSV positive, PICU hospitalization rate was 5.7%. 
There were few complications: respiratory (2.8%); concurrent bacterial sepsis (5.5%). 
Only 3.3% children had received prophylaxis. 1 death was attributed to RSV infec-
tion. CONCLUSIONS: Majority of admissions comprised infants ≤2 years of age. 
63.3% were ≥36 weeks gestation without underlying disease and in total 88.4% would 
not qualify for prophylaxis. Current Canadian RSV prophylaxis guidelines have sig-
niﬁ cantly impacted PICU admission rates in high-risk infants.
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OBJECTIVES: Glutamine, although abundant in human tissue, can become condition-
ally essential in clinical conditions with hyper-catabolism and glutathione depletion 
(burns, pancreatic necrosis, surgical complications), but has not been added to paren-
teral nutrition solutions for a long time, for its alleged non-essentiality and the low 
solubility and stability in aqueous solutions, which have been solved by conjugation 
with alanine. In 2002 a meta-analysis of available trials conducted with alanylgluta-
mine dipeptide revealed signiﬁ cant reductions of mortality, infections and ICU length 
of stay. Since then, data from other trials have become available. Aim of the present 
study is to update the treatment effect estimates by means of a series of Bayesian 
random effects models. METHODS: We searched EMBASE and Medline for clinical 
trials of standard total parenteral nutrition (TPN) vs. TPN + parenteral alanylgluta-
mine in critically ill patients reporting hospital mortality, relative ICU-incident infec-
tion rate, and relative hospital length of stay. For each outcome, a series of Bayesian 
random effects models was speciﬁ ed, in which the treatment effect observed in the 
individual trials is assumed to be drawn from a common distribution and expressed 
as a relative risk or duration. RESULTS: Outcomes from 15 trials and 781 patients 
were retrieved. The main models, i.e. simple hierarchy random effects models with 
neutral priors, estimate a relative mortality of 0.70 (95% CrI: 0.46–0.97), a relative 
infection rate of 0.71 (95% CrI: 0.49–0.97), and a relative length of stay of 0.91 (95% 
CrI: 0.76–1.00). Secondary analyses indicated some heterogeneity in the magnitude 
and reliability of the beneﬁ ts in sub-groups of the wider critically ill patient population. 
The incorporation of prior knowledge leads to signiﬁ cantly more precise estimates and 
permits to obtain comfortable reliability even on subgroup-speciﬁ c treatment effects 
estimates. CONCLUSIONS: In conclusion, the available evidence supports a highly 
credible beneﬁ cial effect of alanylglutamine on mortality, infections and hospital 
length of stay in ICU-admitted critically ill patients.
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OBJECTIVES: In reimbursement ﬁ les models estimate the events avoided over time 
with new interventions. Simulations are performed in the absence of long-term obser-
vational data. In this study observed hospitalization data prior- and post-rotavirus 
vaccination in Belgium were compared to predicted (i.e. modeled) results after 1,2 and 
3 years. METHODS: A Markov cohort model estimated over time the number of 
hospitalizations potentially avoided with rotavirus vaccination in Belgium. We 
adjusted the model to the observed vaccine coverage and to RotarixTM vaccine efﬁ cacy 
from clinical trials. The obtained modeling results were compared with observed data 
collected from 9 Belgian hospitals (2 years pre- and 3 consecutive years post-vaccina-
tion). The outcomes of both studies are expressed as a percentual decrease in hospi-
talizations for 2 age-groups (<2 and <5 years old), after each year post-vaccination. 
The differences are presented in absolute and relative (%) differences for each subse-
quent year post-vaccine launch. RESULTS: The observed data provided slightly better 
outcomes than the modeled results. After 1 year the absolute difference in decrease of 
hospitalizations between observed and modeled data was 3% (11%) for both age-
groups. After 2 years the absolute differences were 3.5% (6%) and 6% (12%) for the 
2 y and 5 y age-group respectively. In the last observation year the absolute differences 
were respectively 2.8% (4%) and 9.3% (13%). CONCLUSIONS: Compared with the 
observed data the model estimates are conservative. The more favorable observational 
results are explained by the indirect vaccine effect on non-vaccinated age-groups which 
is not captured by the static model. The relatively better model ﬁ t in the <2 y old with 
increasing time is explained by the accumulated vaccine impact over time: from 26% 
(1st year) to 68% (3rd year). Rotarix is a trademark of the GlaxoSmithKline group of 
companies.
PIH5
PHARMACOEPIDEMIOLOGICAL BURDEN OF PREGNANCY IN BELARUS
Gavrilenko L, Romanova I, Kozhanova I
Belarusian State Medical University (BSMU), Minsk, Belarus
OBJECTIVES: Application of medicines during pregnancy is a challenge of clinical 
pharmacology. We have analyzed priorities of physicians while choosing medications 
in the course of various diseases during pregnancy and adherence of pregnant women 
to the appointed treatment in Belarus. METHODS: It was prospective multi-center 
cross-sectional epidemiological research. We interviewed 1334 pregnant women and 
619 physicians with diverse specialties in 6 regions of the country using a structured 
questionnaire from January to December 2009. All questionnaires have undergone 
statistical analysis. RESULTS: We found that 34.5% of the pregnant women who 
took part in questioning have had chronic diseases. Medical products were prescribed 
for 91.7% (1223) women. a total of 23.8% of them have received more than 5 medical 
products. Vitamins and drugs with microcells (magnesium, iodine, iron and calcium), 
herbal drugs (valerian, leonurus and eleutherococcus) were in the lead in structure of 
prescription. 91,8% of the pregnant women took all prescribed medicines. 7.7% (103) 
women took antibacterial medicines following recommendations of the doctor. a total 
fo 365 women (27.3%) took medicines without prescription (625 cases). Non-pre-
scribed drugs during pregnancy had mostly been recommended by family or friends 
(24.1% of women) and pharmacists in drugstores (24.1%). CONCLUSIONS: Preg-
nant women in Belarus are active consumers of medicines (vitamins, microcells, herbal 
drugs, bioadditives) themselves and with doctors’ prescription. The widespread use of 
medicines indicates an increased need for documentation and education about the 
safety of medicines in the course of pregnancy. Application of these medications 
creates additional ﬁ nancial burden (in addition to necessary medicines and products), 
and it does not necessarily positively inﬂ uence health. Educational programs for 
pharmacists, doctors and pregnant women are necessary for improvement of drug 
administration.
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OBJECTIVES: Belgium is one of the few countries to implement rotavirus vaccination 
within its universal paediatric immunization programme. This study was designed to 
measure the impact of rotavirus vaccination on acute gastroenteritis (AGE) related 
emergency room (ER) visits in children aged ≤5 years in Belgium. METHODS: A 
retrospective observational study was performed across 11 Belgian participating 
centres. Each centre provided an anonymised list of all ER visits of children aged ≤5 
years during the periods June 2004–May 2006 (pre-vaccine period) and June 2007–
May 2009 (post-vaccine). a sample of 7620 ER visits (3699 pre-vaccine; 3921 post-
vaccine) was randomly selected from the 180,253 ER visits reported. Patient 
demographics and information on the reason for ER visit were collected from all 
randomly selected visits. If the visit was AGE-driven, additional data were collected 
on vaccination status, symptoms, tests performed, treatment, and visit outcome. 
RESULTS: The proportion of AGE-driven ER visits was 11% in the 2-year pre-vaccine 
period (N AGE-driven visits/Total N ER visits = 412/3,699). After insigniﬁ cant change 
to 10.5% during the 1st year after vaccine introduction (N = 208/1,977), this propor-
tion signiﬁ cantly declined to 8.2% (26.6% reduction; p-value < 0.001) in the 2nd year 
(N = 159/1,944). a strong seasonal effect exists in the proportion of AGE-driven ER 
visits on the total number of ER visits, peaking in February and March. The number 
of patients who needed to be hospitalised because of AGE declined over time (from 
a yearly average of 94 pre-vaccine to 62 and then 44 in the 2 consecutive years post 
vaccine introduction). Oral and IV rehydration are the most commonly used treat-
ments. Their use also declined after vaccine introduction. CONCLUSIONS: A signiﬁ -
cant decline in AGE-driven ER visits and subsequent hospitalizations was observed in 
Belgium after introduction of a universal mass vaccination program against rotavirus. 
AGE cases appeared less severe.
